Earnings Releases

Inhibrx Biosciences, Inc. reported the first quarter of 2026 results: net income $33.4 million, EPS $2.15 per share.

“Net loss was $33.4 million during the first quarter of 2026, or $2.15 per share, basic and diluted”

APPLIED MATERIALS INC /DE reported second quarter ended April 26, 2026 results: revenue $7,910 million, net income $2,806 million, EPS $3.51.

“986-7977 mike_sullivan@amat.com Media Contact: Ricky Gradwohl (408) 235-4676 ricky_gradwohl@amat.com APPLIED MATERIALS ANNOUNCES SECOND QUARTER 2026 RESULTS • Record revenue $7.91 billion, up 11 percent year over year • GAAP gross margin 49.9 percent and non-GAAP gross margin 50.0 percent • Record GAAP EPS $3.51 and record non-GAAP EPS $2.86, up 33 percent and 20”

Clipper Realty Inc. reported the three months ended March 31, 2026 results: revenue $38.1 million, net income net loss of $11.1 million.

“Quarterly revenues of $38.1 million for the first quarter of 2026 vs $39.4 million for the first quarter of 2025, including quarterly residential revenues of $31.9 million for the first quarter of 2026 vs $29.2 million for the first quarter of 2025, an increase of $2.7 million, or 9.3% and quarterly commercial revenues for the first quarter of 2026 of $6.2 million vs $10.2 million for the first quarter of 2025, a decrease of $4.0 million.”

Unusual Machines, Inc. reported the first quarter ended March 31, 2026 results: revenue $8.1 million, net income over $10 million.

“In the first quarter, we generated $8.1 million in revenue, reflecting a 296% year-over-year growth compared to the first quarter of 2025 and a 65% quarter-over-quarter growth over the fourth quarter of 2025. We are profitable and generated over $10 million in net income in the first quarter.”

AirJoule Technologies Corp. reported financial results for first quarter of 2026.

“AirJoule Technologies Corporation (NASDAQ: AIRJ) (“AirJoule Technologies” or “AIRJ”), a leading platform technology that unleashes the power of water from air, today announced its results for the first quarter of 2026 and provided a business update on its progress toward commercialization.”

Glimpse Group, Inc. reported financial results for third quarter fiscal year 2026, ended March 31, 2026.

“On May 14, 2026, The Glimpse Group, Inc. (the “Company”) issued a press release announcing financial results for its quarter ended March 31, 2026.”

SANGAMO THERAPEUTICS, INC reported first quarter ended March 31, 2026 results: revenue $1.4 million, net income $31.0 million, EPS $0.08 per share.

“First Quarter 2026 Financial Results Consolidated net loss for the first quarter ended March 31, 2026 was $31.0 million, or $0.08 per share, compared to a consolidated net loss of $30.6 million, or $0.14 per share, for the same period in 2025. Revenues Revenues for the first quarter ended March 31, 2026 were $1.4 million, compared to $6.4 million for the same period in 2025.”

EGAIN Corp reported its fiscal 2026 third quarter ended March 31, 2026 results: revenue $22.5 million, net income $2.4 million, EPS $0.09 per share on a basic and diluted basis.

“week, we announced four new products on our platform to strong customer interest at eGain Solve London. ​ Fiscal 2026 Third Quarter Financial Highlights ​ ● Total revenue was $22.5 million, up 7% year over year. ● AI Knowledge Hub annual recurring revenue grew 26% year over year to $48.0 million, contributing 64% of total SaaS annual recurring revenue. ● GAAP gross”

Dare Bioscience, Inc. reported financial results for the quarter ended March 31, 2026.

“On May 14, 2026, Daré Bioscience, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026, a copy of which is furnished as Exhibit 99.1 to this report.”

INTELLINETICS, INC. reported the three months ended March 31, 2026 results: revenue $3,909,182, net income $1,177,853, EPS ($0.27). Guidance initiated.

“Revenues for the three months ended March 31, 2026 were $3,909,182, a decrease of 8.0%, as compared with $4,247,345 for the same period in 2025. This decrease was primarily due to a 14.3% decline in professional services revenue. Total operating expenses increased 4.4% to $3,664,611, compared to $3,511,759 for the same period in 2025, driven by increases in general and administrative expense of 9.1%, due to non-recurring expenses in Q1 related to our CEO transition, totaling $430,130, including severance costs and share-based compensation for our retiring CEO, overlapping compensation expenses for our prior and current CEO in the quarter, and recruiting costs for our new CEO, partially offset by reduced share-based compensation expense for other employees. Loss from operations was $1,182,552 compared to loss from operations of $684,559 in the first quarter last year, primarily due to the lower professional services revenues and non-recurring CEO transition costs. Intellinetics reported”

CVD EQUIPMENT CORP reported first quarter ended March 31, 2026 results: revenue $1.8 million, net income ($1.7 million), or ($0.25) per basic and diluted share, EPS ($0.25) per basic and diluted share.

“from a vertically integrated fabrication model to outsource fabrication for certain components. This action is expected to reduce our annual operating costs by approximately $1.8 million in fiscal 2026.” Lakios added, “In addition, we remain focused on delivering solutions across our key target markets, including aerospace and defense, industrial applications”

Presurance Holdings, Inc. reported first quarter ended March 31, 2026 results: revenue $5,925, net income $2,622, EPS $0.15.

“% Change (dollars in thousands, except share and per share amounts) Gross written premiums $ 11,469 $ 16,173 -29.1 % Net written premiums 6,075 10,840 -44.0 % Net earned premiums 5,925 10,315 -42.6 % Net investment income 1,110 1,289 -13.9 % Net realized investment gains (losses) (14 ) 3 ** Change in fair value of equity securities 30 (192 ) ** Net income (loss)”

NETSOL TECHNOLOGIES INC reported Q3 FY2026 results: revenue $19.8 million, net income $1.3 million, EPS $0.11 per diluted share. Guidance reaffirmed.

“Third Quarter Fiscal 2026 Financial Results Total net revenues for the third quarter of fiscal 2026 were $19.8 million, a record for the company, compared with $17.5 million in the prior-year period, an increase of 13.0%. Recurring subscription and support revenues for the third quarter were $8.8 million, an increase of 11.7%, compared with $7.9 million in the prior-year period. License fees for the third quarter were $4.7 million, compared with $1,198 in the prior-year period. The increase reflected higher license fees associated with the recognition of a one-time license investment from a four-year, $50 million contract extension with one of NETSOL’s longest-tenured tier-one global auto captive customers. Services revenues for the third quarter were $6.3 million, compared with $9.7 million in the prior-year period, primarily reflecting the timing and composition of current implementation projects, as well as a one-time approximately $2.4 million pickup in the prior-year period associ”

NextPlat Corp reported the quarter ended March 31, 2026 results: revenue $9.9 million, net income approximately $1.1 million, EPS ($0.42) per diluted share.

“Consolidated revenue for the quarter ended March 31, 2026, was approximately $9.9 million, compared to approximately $13.9 million for the prior year period, an overall decrease of 29% which reflects the expected decline in overall healthcare revenue.”

FITLIFE BRANDS, INC. reported first quarter ended March 31, 2026 results: revenue $25.3 million, net income $1.7 million, EPS $0.18 per basic share and $0.17 per diluted share.

“products, today announced financial results for the first quarter ended March 31, 2026. Highlights for the first quarter ended March 31, 2026 include: ● Total revenue was $25.3 million, an increase of 59% compared to the first quarter of 2025. ● Wholesale revenue was $14.1 million, or 56% of total revenue, an increase of 166% compared to the first quarter of”

Monopar Therapeutics reported first quarter ended March 31, 2026 results: net income Net loss for the first quarter of 2026 was $3.9 million, or $0.46 per share, EPS $0.46 per share.

“Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates”

SPRUCE POWER HOLDING CORP reported first quarter ended March 31, 2026 results: revenue $23.4 million, net income $2.9 million net loss, EPS $0.16 per share.

“Revenues totaled $23.4 million for the first quarter of 2026 , compared with $23.8 million for the first quarter of 2025. Revenues for the first quarter are in line with prior year revenues, representing stable asset performance. Total operating expenses were $19.6 million for the first quarter of 2026, compared to $25.5 million for the first quarter of 2025. The year-over-year decline in operating expense is attributed primarily to a decrease in operations and maintenance costs and ongoing cost management efforts implemented in the third quarter 2025. Core Operating Expenses, which includes both SG&A expenses and O&M expenses was $12.7 million in the aggregate for the first quarter of 2026, down from $18.6 million in the year-earlier period. This includes $11.6 million of SG&A expenses and O&M expenses of $1.2 million in the first quarter of 2026, down from SG&A expense of $14.7 million and O&M expense of $3.9 million for the first quarter of 2025. The decreases in both total operatin”

Fidelity Private Credit Fund reported financial results for Q1 2026.

“INVESTMENT STRATEGY QUARTERLY Fidelity Private Credit Fund Q1 2026”

AMERICAN SHARED HOSPITAL SERVICES reported first quarter ended March 31, 2026 results: revenue $7.1 million, net income $(0.6) million.

“and advanced radiation therapy cancer treatment services, today announced financial results for the first quarter ended March 31, 2026. Key Financial Highlights ● Total revenue: $7.1 million, compared with $6.1 million in the first quarter of 2025, an increase of 15.9% ● Gross margin: Increased 36.7% to $1.3 million, or 18.2%, compared with $0.9 million, or 15.4%, in”

LIVE VENTURES Inc reported its fiscal second quarter ended March 31, 2026 results: revenue $102.9 million, net income $2.4 million, EPS $0.80.

“a diversified holding company, today announced financial results for its fiscal second quarter ended March 31, 2026. Fiscal Second Quarter 2026 Key Highlights: ● Revenue was $102.9 million, compared to $107.0 million in the prior-year period ● Gross margin increased 80 basis points to 33.6%, compared to 32.8% in the prior-year period ● Operating loss was $2.0”

TRIO-TECH INTERNATIONAL reported fiscal third quarter ended March 31, 2026 results: revenue $16.5 million, net income Net loss attributable to common shareholders: $38 thousand, or approximately breakeven per diluted share, EPS approximately breakeven per diluted share.

“discipline, we remain focused on executing our strategy and positioning the Company for sustainable growth.” Fiscal 2026 Third Quarter Financial Results • Total revenue: $16.5 million, a 124% increase from $7.4 million in Q3 FY2025. • Semiconductor Back-End Solutions: $13.1 million, up 141% from $5.4 million in the prior year quarter, driven by higher testing”

Ideal Power Inc. reported first quarter ended March 31, 2026 results: net income Net loss in the first quarter of 2026 was $3.6 million.

“Ideal Power Reports First Quarter 2026 Financial Results”

INNOVATIVE SOLUTIONS & SUPPORT INC reported fiscal second quarter ended March 31, 2026 results: revenue $22.4 million, net income $3.4 million, EPS $0.19 per diluted share.

“quarter financial results for the three-month period ended March 31, 2026. SECOND QUARTER FISCAL 2026 HIGHLIGHTS (all comparisons versus the prior year period) ​ ● Net sales of $22.4 million, +2.0% ● Gross profit of $11.4 million; gross margin of 51.1% ● Net Income of $3.4 million, or $0.19 per diluted share ● Adjusted Net Income (1) of $4.8 million, or $0.26 per”

Dogwood Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $5.0 million, EPS $0.15 basic and diluted net loss per share.

“On May 14, 2026, Dogwood Therapeutics, Inc. (the “Company”) issued a press release announcing the results of operations for the first quarter ended March 31, 2026.”

Senti Biosciences, Inc. reported the first quarter ended March 31, 2026 results: net income $4.2 million, or $0.14 per basic and diluted share.

“Net loss was $4.2 million, or $0.14 per basic and diluted share, for the first quarter of 2026”

GRI Bio, Inc. reported three months ended March 31, 2026 results: net income approximately $2.0 million.

“Net loss for the quarter ended March 31, 2026, was approximately $2.0 million, compared to approximately $3.0 million for the same period in 2025.”

XTI Aerospace, Inc. reported first quarter ended March 31, 2026 results: revenue $27.7 million. Guidance initiated.

“2026, and provided an update on the Company’s outlook for 2026. 2026 first quarter highlights (Inpixon results excluded and reflected in discontinued operations): ● Revenue of $27.7 million ● Gross profit of $5.1 million ● Gross profit as a percentage of revenue of 18.6 percent 2026 Financial Outlook and Guidance (1) : The Company expects to achieve the following”

Synergy CHC Corp. reported the three months ended March 31, 2025 results: revenue $8.17 million, net income $0.88 million, EPS $0.10.

“$8.17 million. ● Gross margin of 72.3% vs. 75.4%. ● Income (loss) from operations of ($0.57) million”

Synergy CHC Corp. reported the three months ended March 31, 2026 results: revenue $5.49 million, net income ($2.57) million, EPS ($0.23).

“path, we expect 2026 to be a year of sustainable growth and value creation for our shareholders.” First Quarter 2026 Financial Summary vs. Same Year-Ago Period ● Revenue of $5.49 million vs. $8.17 million. ● Gross margin of 72.3% vs. 75.4%. ● Income (loss) from operations of ($0.57) million vs. $1.95 million. ● Net income (loss) of ($2.57) million vs.”

Candel Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.

“On May 14, 2026, Candel Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026.”

Ondas Inc. reported the first quarter ended March 31, 2026 results: revenue $50.1 million. Guidance raised.

“Ondas Reports Record First Quarter 2026 Financial Results: Raises Full Year 2026 Revenue Forecast to $390 Million Q1 2026 revenue of $50.1 million”

FORUM MARKETS Inc reported the first quarter ended March 31, 2026 results: revenue $2.9 million. Guidance lowered.

“First Quarter 2026 GAAP Financial Highlights (in millions) For the Quarter Ended March 31, 2026 Revenue $ 2.9 Gross Profit $ 2.9 Cash and Cash Equivalents $ 65.9 ● Revenue of $2.9 million, driven primarily by aircraft engine lease revenue of $1.1 million, staking revenue of $1.8 million ● Net loss from Continuing Operations of $77.5 million, primarily”

Cingulate Inc. reported the quarter ended March 31, 2026 results: net income Net loss was $9.3 million for the three months ended March 31, 2026.

“Cingulate Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026 and providing a business update.”

Benitec Biopharma Inc. reported third fiscal quarter ended March 31, 2026 results: net income Net loss attributable to shareholders for the quarter ended March 31, 2026, was $11.9 million, or $(0.24) per basic and, EPS $(0.24) per basic and diluted share.

“Net loss attributable to shareholders for the quarter ended March 31, 2026, was $11.9 million, or $(0.24) per basic and diluted share”

MeiraGTx Holdings plc reported financial results for first quarter ended March 31, 2026.

“On May 14, 2026, MeiraGTx Holdings plc (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.”

Lucid Diagnostics Inc. reported the first quarter ended March 31, 2026 results: revenue $1.3 million, net income $23.6 million, EPS $(0.17) per common share.

“(EX-99.1) --- Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results Processed 3,177 EsoGuard ® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and a runway that extends into 2027 and past upcoming reimbursement milestones Conference call and webcast to be held today, May”

Clene Inc. reported first quarter 2026 results: net income net loss of $8.1 million , or $0.69 per share, EPS $0.69 per share.

“Clene reported a net loss of $8.1 million , or $0.69 per share, for the quarter ended March 31, 2026 , compared to a net loss of $0.8 million , or $0.09 per share, for the same period in 2025 .”

Keros Therapeutics, Inc. reported quarter ended March 31, 2026 results: net income $23.7 million.

“Keros reported a net loss of $23.7 million in the first quarter of 2026”

Biofrontera Inc. reported first quarter of 2026 results: revenue $10.1 million, net income $4.8 million, or $0.41 per share, EPS $0.41 per share.

“today reported financial results for the three months ended March 31, 2026 and provided a business update. First Quarter Financial Highlights ● Revenues for Q1 2026 were $10.1 million, a ~17% increase compared to $8.6 million for the same period in 2025. ● Gross margins were about 80%, an 18 percentage points increase compared to approximately 62% in Q1”

Autolus Therapeutics plc reported first quarter ended March 31, 2026 results: revenue $26.2 million. Guidance reaffirmed.

“Therapeutics Reports First Quarter 2026 Financial Results and Business Updates May 14, 2026 at 7:00 AM EDT AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UK Company achieves positive gross margin for the acute lymphoblastic leukemia (ALL)”

Intuitive Machines, Inc. reported first quarter ended March 31, 2026 results: revenue $186.7 million. Guidance raised.

“proposals are underway for CLPS 2.0, Space Reactor‐1 Freedom, and other Moon base infrastructure initiatives Financial Highlights • Achieved record quarterly revenue of $186.7 million, nearly 3x of prior year driven by the Lanteris acquisition along with continued CLPS, OMES, and NSNS execution; Lanteris acquisition closed on January 13, 2026; reported Q1”

Strive, Inc. reported first quarter ended March 31, 2026 results: net income GAAP net loss of $265.9 million, EPS Non-GAAP adjusted net loss attributable to common stockholders 1 of $319.7 million, or $5.19 per diluted common share 1.

“Strive, Inc. (Nasdaq: ASST; SATA) (“Strive” or the “Company”) today announced that it will begin paying dividends on its Variable Rate Series A Perpetual Preferred Stock (the "SATA Stock") on a daily basis. This change will take effect on June 16, 2026, with dividends paid each business day to stockholders of record on the immediately preceding business day. Dividend, if and when declared, will be declared on a monthly basis for the following month's monthly dividend period. The Company's board of directors maintained the regular dividend rate per annum on the Company's SATA Stock at 13.00%, effective for the monthly periods commencing on or after May 16, 2026. The Company also announced its financial results for the first quarter ended March 31, 2026 . Key Highlights: ▪ Acquired a total of 6,001 bitcoin during the first quarter ended March 31, 2026 , including 5,048 bitcoin from the acquisition of Semler Scientific, Inc. and 953 bitcoin from open market purchases. ▪ Acquired an additi”

Terrestrial Energy Inc. /DE/ reported the first quarter ended March 31, 2026 results: net income net loss of $10.5 million.

“On May 14, 2026, Terrestrial Energy Inc. announced its financial and operating results for the quarter ended March 31, 2026.”

Merlin, Inc. reported first quarter ended March 31, 2026 results: revenue $1.0 million, net income $(90.4) million.

“First quarter 2026 Total revenue of $1.0 million, compared to $0.9 million in the first quarter of 2025 ● First quarter 2026 GAAP net loss of $(90.4) million, compared to $(12.7) million in the first quarter of 2025”

Pyxis Oncology, Inc. reported financial results for the quarter ended March 31, 2026.

“On May 14, 2026, Pyxis Oncology, Inc. (“the Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026 and provided a corporate update.”

Sunrise Realty Trust, Inc. reported quarter ended March 31, 2026 results: net income $4.3 million, EPS $0.32 per basic weighted average common share.

“On May 14, 2026, Sunrise Realty Trust, Inc. issued a press release announcing its financial and operational results for the quarter ended March 31, 2026.”

CorMedix Inc. reported the first quarter ended March 31, 2026 results: revenue $127.4 million, net income $38.6 million, EPS $0.48 and $0.43 per share. Guidance raised.

“reference in such a filing. --- EX-99.1 (EX-99.1) --- CORMEDIX THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ‒ Q1 2026 Net Revenue of $127.4 million ‒ ‒ Q1 2026 Net Income of $38.6 million ; Adjusted EBITDA of $70.0 million ‒ ‒ Company raises FY 2026 Revenue and Adjusted EBITDA Guidance ‒ ‒ Conference Call Scheduled for Today”

enCore Energy Corp. reported first quarter ended March 31, 2026 results: EPS $0.03.

“enCore Energy Reports Q1 2026 Financial Results”

Karyopharm Therapeutics Inc. reported Full-Year 2026 results: revenue Company Reaffirms Full-Year 2026 Total Revenue Guidance of $130 Million to $150 Million Including U.S. XPOVIO Net Produc. Guidance reaffirmed.

“Company Reaffirms Full-Year 2026 Total Revenue Guidance of $130 Million to $150 Million Including U.S. XPOVIO Net Product Revenue Guidance of $115 Million to $130 Million”

Karyopharm Therapeutics Inc. reported first quarter of 2026 results: revenue Total Revenue was $35.1 Million. Guidance reaffirmed.

“Total Revenue was $35.1 Million and U.S. XPOVIO® (selinexor) Net Product Revenue was $29.2 Million for the First Quarter of 2026”